AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00881543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dipeptidyl Peptidase IV inhibitors
Description: Dosage 100 mg each day, once a day, 2 months
Study NCT00881543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipeptidyl Peptidase IV inhibitors
Description: Dosage 100 mg each day, once a day, 2 months
Study NCT02057328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TELMISARTAN
Description: Patients of the group of telmisartan will take 40 mg of telmisartan daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients still classified in the stage I hypertensive range will receive 80 mg of telmisartan daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range will continue on the same medication scheme. For patients still classified in the stage I hypertensive range12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project.
Study NCT01604902 — intervention group
Intervention type: OTHER
Intervention: 4 mm punch biopsies
Description: 4 mm punch-biopsies from lesional and non-lesional psoriatic skin at day 0 and up to four times after treatment at the following days: 4, 14, 28 or 84.
Study NCT03389243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol and metamizole
Description: in group PM patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram and paracetamol in a dose of 1 gram
Study NCT02057328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NEBIVOLOL
Description: Patients will take 5 mg of nebivolol daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients classified in the stage I hypertensive range the nebivolol group will receive 10 mg of nebivolol daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. For patients classified in the stage I hypertensive range 12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project
Study NCT02978313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: Irinotecan+LV5FU2
Study NCT00652262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: Patients received BAY 38-9456 10 mg for the first 4 weeks of the treatment period, and then went on to receive 10 mg or 20 mg for the following 8 weeks.
Study NCT03225521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HeartSteps: A just-in-time adaptive intervention for increasing physical activity amongst sedentary adults.
Description: HeartSteps is an Android-based mHealth intervention that contains two main intervention components: contextually-tailored suggestions for activity and planning of the next day's activity. Activity suggestions provide individuals with actionable suggestions for how they can be active in their current context. Delivered suggestions are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. HeartSteps can deliver a user activity suggestions up to five times a day. Evening planning asks users to create or choose a plan of how they will be active on the following day. Planning can be delivered once a day, in the evening.
Study NCT01969162 — intervention group
Intervention type: PROCEDURE
Intervention: Tear Sample Collection
Description: Tear sample collection as per protocol. No investigational drug is administered in this study.
Study NCT02169947 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss core
Description: The weight loss core is a culturally adapted version of the Diabetes Prevention Program core 16 week session program.
Study NCT01227824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572 (dolutegravir)
Description: GSK1349572 50 mg taken once daily with or without food
Study NCT02169947 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss core
Description: The weight loss core is a culturally adapted version of the Diabetes Prevention Program core 16 week session program.
Study NCT02169947 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss core plus maintenance
Description: The intervention is a culturally adapted version of the Diabetes Prevention Program core 16 sessions plus 12 maintenance sessions.
Study NCT03170323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: steroid 1mg/kg/d and Mycophenolate mofetil 500mg bid
Study NCT01227824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir
Description: raltegravir 400mg taken twice daily
Study NCT01227824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GSK1349572 Placebo
Description: GSK1349572 placebo taken once daily
Study NCT03170323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporins
Description: steroid 0.15mg/kg/d and Cyclosporin 3-5mg/kg/d
Study NCT02927119 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: iodine
Description: ≥ 150 µg/day iodine supplementation (iodine containing pregnancy supplement) prior to enrollment
Study NCT01227824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ABC/3TC
Description: Abacavir/Lamivudine background therapy once daily
Study NCT00779129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Lyposomal Doxorubicin
Description: Caelyx 35 mg/m2 intravenously, on Day 1, every 3 weeks, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
Study NCT00779129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600 mg/m2, intravenously, on Day 1, every 6 weeks, during 6 cycles (concomitantly with Caelyx). Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
Study NCT00507715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plantago ovata husk
Description: 5 g of effervescent powder (3.5 g pf plantago ovata husk) t.i.d. during 14 days
Study NCT01227824 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ABC/3TC
Description: Abacavir/Lamivudine background therapy once daily
Study NCT01227824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TDF/FTC
Description: Tenofovir/emtricitabine background therapy once daily
Study NCT00507715 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: hemicellulose crystalline
Description: 5g effervescent powder t.id. during 14 days
Study NCT03263091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Oral tablets
Study NCT03263091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study NCT00088855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV
Study NCT02724436 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Study NCT01227824 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TDF/FTC
Description: Tenofovir/emtricitabine background therapy once daily
Study NCT01227824 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir Placebo
Description: raltegravir placebo taken twice daily
Study NCT01961583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluciclatide
Description: Baseline 18F-Fluciclatide PET imaging will be obtained before starting of Pazopanib therapy(within 7 days).~Subsequent 18F-Fluciclatide PET should be performed on 7 days after Pazopanib therapy
Study NCT02812888 — intervention group
Intervention type: DRUG
Intervention: thionamide treatment for 3 months
Description: Hyperthyroid patients would received thionamide treatment (methimazole, propylthiouracil, or propranolol) for 3 months, and euthyroidism would be obtained.
Study NCT00484185 — intervention group
Intervention type: DRUG
Intervention: BeneFIX (coagulation factor IX (recombinant))
Description: BeneFIX will be administered according to physician's discretion.
Study NCT04052802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fissure sealing
Description: The materials will be applied to the demineralized fissures as stated in manufacturer's instructions
Study NCT01247298 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: This investigational study will evaluate the combination of TACE along with high dose SBRT. TACE has been used extensively in the palliative treatment of hepatocellular carcinoma (HCC). It will be performed by the Interventional Radiologist prior to radiation therapy.
Study NCT04607798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency and pulsed electro-magnetic fields treatment
Description: Radiofrequency and pulsed electro-magnetic fields treatment of the vaginal canal to maintain an internal temperature of approximately 42 C for the proximal thermometer and 45 C for the mid and distal thermometers for 15 minutes.
Study NCT03203876 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lirilumab
Description: Specified dose on specified days
Study NCT03203876 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT03203876 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT02724436 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radioembolization with Y-90
Description: radioembolization with Y-90
Study NCT00243321 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high dose-rate brachytherapy
Description: High dose-rate brachytherapy
Study NCT00243321 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: intensity-modulated radiation therapy
Study NCT02700256 — intervention group
Intervention type: BEHAVIORAL
Intervention: survey
Description: All patients will submit a baseline survey following enrollment onto study. After successful completion of the AXR or 24-hour discharge pathway, the consented patient will be contacted by email or telephone for 5 days following discharge from surgery.
Study NCT02320396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Description: Desloratadine 5 mg tablets
Study NCT02320396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT03977207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine Sodium
Description: Thyroid hormone supplement
Study NCT02688374 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment A: Nicorette 2 mg coated mint gum
Description: Participants will be administered with 2 mg coated mint gum of Nicorette
Study NCT03977207 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo oral capsule
Study NCT02508064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068
Study NCT01670201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex Transfer Ag
Description: Silver dressing
Study NCT02012010 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual syringe infusion method
Description: Infuse the distension medium of hysteroscopy by manual syringe infusion method
Study NCT02012010 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pump infusion method
Description: Infuse the distension medium of hysteroscopy by pump infusion method
Study NCT03001544 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TS23
Description: comparison of different doses
Study NCT04209738 — intervention group
Intervention type: OTHER
Intervention: This is an observational study being conducted as a substudy of another trial.
Description: This is an observational study being conducted as a substudy of another trial. No intervention is planned for Substudy.
Study NCT00609921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARQ197
Description: treatment
Study NCT02555800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients will receive 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) every 3 to 6 weeks in a submucosal plane after surgical debulking. 12.5 mg of bevacizumab diluted in 3mL of 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
Study NCT02555800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cidofovir
Description: Patients will receive 3 intralesional injections of cidofovir every 3 to 6 weeks a submucosal plane after surgical debulking. 3.5 mL of cidofovir diluted to a concentration of 5 mg/mL in a 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
Study NCT02555800 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution
Study NCT03021837 — intervention group
Intervention type: OTHER
Intervention: antenatal corticosteroid
Description: Will look at maternal glucose level after corticosteroids
Study NCT02267928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Check Symptoms
Description: Symptoms are Checked
Study NCT02267928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uncheck Symptoms
Description: Symptoms are Un-checked
Study NCT02267928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experienced
Description: Focus of instructions is on symptoms the participant has experienced
Study NCT02267928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Not Experienced
Description: Focus of instructions is on symptoms the participant has NOT experienced
Study NCT01501487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAC chemotherapy
Description: Docetaxel 75 mg/m2 IV day 1, Doxorubicin 50 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1; Cycled every 21 days for 6 cycles
Study NCT01501487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TC chemotherapy
Description: Docetaxel 75 mg/m2 IV day 1, Cyclophosphamide 600 mg/m2 IV day 1; Cycled every 21 days for 6 cycles
Study NCT01501487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy
Description: Doxorubicin 60 mg/m2 IV day 1, Cyclophosphamide 600 mg/m2 IV day 1, Cycled every 14 days for 4 cycles, OR 5-Fluorouracil 500 mg/m2 IV day 1, Epirubicin 100 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1; Cycled every 21 days for 3 cycles Followed by Paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 weeks, OR Docetaxel 100mg/m2 IV day 1 cycled every 21 days for 3 or 4 cycles
Study NCT01501487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCH chemotherapy
Description: Docetaxel 75 mg/m2 IV day 1, followed by Carboplatin AUC 6 IV day 1; Cycled every 21 days for 6 cycles Trastuzumab initial dose of 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks, OR initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30-90 minutes IV infusion every three weeks for 52 weeks.
Study NCT01501487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: T + trastuzumab followed by CEF + trastuzumab
Description: Trastuzumab 4 mg/kg IV for one dose beginning just prior to first dose of paclitaxel.~Followed by trastuzumab 2 mk/kg IV weekly for 23 weeks Paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 wks Followed by 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles Trastuzumab 6mg/kg IV every 21 days for 9 cycles to complete 1yr
Study NCT01501487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dose dense AC followed by T + trastuzumab
Description: Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 (cycled every 14 days for 4 cycles) Followed by paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 wks All cycles are with filgrastim support with trastuzumab 2 mg/kg (4 mg/kg loading dose).~Following chemotherapy , trastuzumab to continue every 3 weeks at 6 mg/kg for the duration of 1 week.
Study NCT01501487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dose dense AC followed by T + trastuzumab + pertuzumab
Description: Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles Followed by docetaxel 75-100 mg/m2 by 1 h IV infusion weekly for 12 wks All cycles are with filgrastim support with trastuzumab 6 mg/kg (8 mg/kg loading dose with C1) Pertuzumab 420 mg (840 mg loading dose with C1). Following chemotherapy, trastuzumab to continue every 3 weeks at 6 mg/kg for the duration of 1 week.
Study NCT01501487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTH followed by dose dense AC of FEC
Description: Docetaxel 75-100 mg/m2 by 1 h IV infusion Cycled every 21 days for 4 cycles With Trastuzumab 6 mg/kg IV (8 mg/kg IV loading dose) q3W And Pertuzumab 420 mg IV (840 mg IV loading dose) q 3w +/- pegfilgrastim 6 mg sq on day 2-3,~Followed by 4 cycles of AC or FEC:~AC Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles with pegfilgrastim 6 mg sq on day 2 FEC 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles~In all of the above mentioned regimens docetaxel might be substituted with paclitaxel as paclitaxel is better tolerated but is expected to have the same efficacy as docetaxel.
Study NCT03427437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: caudal block was performed by conventional and ultrasound method with %0,25 bupivacaine + 1/200000 adrenalin
Study NCT03427437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenalin
Description: caudal block was performed by conventional and ultrasound method with %0,25 bupivacaine + 1/200000 adrenalin
Study NCT03427437 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: caudal block was performed by ultrasound method
Study NCT00932087 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample
Description: Blood sample for lipidomic study
Study NCT00824564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid plus standard of care
Description: Tranexamic acid given slowly intravenously (15 mg/kg body weight) 15 minutes before surgery followed by a second dose at three hour interval from first dose and third dose at three hour interval from the second + Standard of care (Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss)
Study NCT00824564 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of care
Description: Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss
Study NCT03312192 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interbody Cage
Description: Anterior cervical discectomy and fusion with interbody cage placement
Study NCT03312192 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interbody Cage and Anterior Plating
Description: Anterior cervical discectomy and fusion with interbody cage placement and anterior plating
Study NCT02588456 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART22 cells
Description: CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB administered by IV infusion.
Study NCT03006783 — intervention group
Intervention type: PROCEDURE
Intervention: Cross-face nerve graft
Description: connecting the healthy facial nerve to the affected facial nerve
Study NCT02262637 — intervention group
Intervention type: DRUG
Intervention: Micardis®
Study NCT02262637 — intervention group
Intervention type: DRUG
Intervention: MicardisPlus®
Study NCT04926480 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: low and high flow Anesthesia
Description: comparison of hemodynamic changes in low and high flow anesthesia groups
Study NCT04926480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low and high flow Anesthesia
Description: comparison of hemodynamic changes in low and high flow anesthesia groups
Study NCT02114190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescent Mindful Eating Group
Description: Adolescents will learn mindfulness and meditation, how to be mindful when eating, mindful yoga, how to recognize hunger cures, understand emotional eating, trigger foods and how to apply mindful eating in social situations.
Study NCT02114190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Integrated Group
Description: Adolescents will receive learn same techniques as adolescents in Adolescent Mindful Eating Group. The group component of the parent intervention is designed for parents only and will be run parallel to the adolescent group. The goal of these sessions is to teach parents skills to support adolescent by developing effective parenting styles, parenting skills, strategies around eating behavior change, productive problem solving, and the role of all other family members with regard to the treatment process. The last five sessions will be dedicated to teaching a slightly reduced MEAL adult protocol to allow parents to learn mindfulness skills as it applies to their own eating behaviors and affective reactivity.